Latest updates suggest that new pancreatic cancer treatment moves to the next level. According to reports, a study conducted by researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and published in the journal Nature Medicine found a therapeutic approach that may be beneficial for improving the quality of life in cancer patients. The researchers stated that the therapy involving the combination of drugs may help treat individuals diagnosed with the condition.
This is good news for individuals diagnosed with pancreatic cancer as the condition has become more prevalent in recent years. According to a report, the treatment shows promise as the HCI researchers have successfully observed the impact of the therapy both in a laboratory and on a human subject. Currently, the study has moved on to a clinical trial that has commenced at HCI. Even though no specific date is specified. The clinical trial is expected to open at other locations in the United States very soon.
“We were able to observe that the combination of these two drugs — which, when used individually, don’t have much of an impact on the disease — appears to have a very potent impact on the growth of pancreatic cancer. We have observed this in the lab in Petri dishes, then in mouse models, and now in a pancreatic cancer patient on a compassionate use basis. Indeed, we proceeded from a petri dish to a patient in less than two years — a timeline that is rarely seen in medical science,” one of the lead authors of the study, a cancer researcher at HCI and Professor of Dermatology at the U of U Martin McMahon, Ph.D. said.
You can find more information about the ongoing clinical trial entitled THREAD with the National Clinical Trial Number – 03825289. It is important to state that the therapy utilizes two drugs that are already approved by the Food and Drug Administration for the treatment of other conditions, cancer inclusive. In order to combat pancreatic cancer with the drugs, they will need to be administered orally. including cancer. The new drug combination is administered through pills taken orally.